Abstract
Ibrutinib, a first-in-class Bruton tyrosine kinase inhibitor taken once daily, is approved in the United States for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and allows for treatment without chemotherapy. Extended treatment with ibrutinib has demonstrated increased complete response (CR) rates over time. To analyze baseline factors that predict CR in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with ibrutinib. Univariate and multivariate analyses of pooled data from 2 clinical trials were used to assess the prognostic value of baseline factors associated with CR in 327 patients from the PCYC-1102 and PCYC-1112 studies treated with single-agent ibrutinib. Participants were followed up in academic and community medical centers in the United States, the United Kingdom, Australia, France, Italy, Ireland, Poland, Spain, and Austria. Odds ratio (OR) of CR rate. The 327 patients included in this analysis had a median age of 67 years (range, 30-86 years) and 227 (69.4%) were male. At baseline, 185 patients (56.6%) had bulky disease (lymph node ≥5 cm), 184 (56.3%) had advanced-stage disease, and 182 (55.7%) had an Eastern Cooperative Oncology Group performance status of 1 or h...Continue Reading
Citations
Jul 13, 2018·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Aug 23, 2018·American Journal of Hematology·Anthony R MatoChadi Nabhan
May 3, 2019·Current Hematologic Malignancy Reports·Adam S KittaiAlexey V Danilov
Aug 6, 2019·Cancer·Emili Montserrat, Robert Peter Gale
Jan 3, 2020·Blood·Paolo StratiJan A Burger
Mar 31, 2019·Targeted Oncology·Fabienne Lucas, Jennifer A Woyach
May 13, 2018·Blood·John G Gribben
Mar 12, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexey V DanilovChristopher D Fegan
Oct 31, 2020·Leukemia·Tingyu WenPeng Liu
Apr 4, 2021·Cancers·Moritz Fürstenau, Barbara Eichhorst
Sep 4, 2020·Journal of Managed Care & Specialty Pharmacy·Qing HuangNora Janjan
May 9, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian BrieghelCarsten U Niemann
Aug 28, 2021·Journal of Personalized Medicine·Katharine L Lewis, Chan Y Cheah
Nov 19, 2021·Cancer Medicine·David E SpanerYonghong Shi
Dec 11, 2021·Hematology·Constantine S Tam